Status | Study |
Completed |
Study Name: Rituximab in Hairy Cell Leukemia: a Multicenter Retrospective Study Condition: Hairy-cell Leukemia Date: 2016-08-25 Interventions: Other: Data collection |
Recruiting |
Study Name: Clinical Research in Hairy Cell Leukemia:Surveillance and Documentation of Clinical Outcomes Condition: Leukemia, Other Date: 2015-08-20 |
Completed |
Study Name: Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab Condition: Hairy Cell Leukemia (HCL) Date: 2014-05-21 Interventions: Drug: 2CdA +/- Rituximab Cladribine 0.14 mg/kg daily subcutaneous bolus injection Rituximab 375 mg/m |
Recruiting |
Study Name: Therapy Optimisation for the Treatment of Hairy Cell Leukemia Condition: Hairy Cell Leukemia Date: 2014-04-30 Interventions: Drug: Cladribine s.c. injection, HCL treatment Patients with hairy cell leukemia and the need for treatm |
Active, not recruiting |
Study Name: Bortezomib and Filgrastim in Promoting Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Stem Cell Transplant Condition: Adult Grade III Lymphomatoid Granulomatosis B-cell Chronic Lymphocytic Leukemia Date: 2014-01-14 Interventions: Drug: bortezomib Given IV |
Recruiting |
Study Name: Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia Condition: Hairy Cell Leukemia Hairy Cell Leukemia Date: 2013-04-24 Interventions: Drug: Ibrutinib Given PO |
Active, not recruiting |
Study Name: Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia Condition: Leukemia, Hairy Cell Date: 2013-04-09 Interventions: Drug: moxetumomab pasudotox Drug: IV Bag P |
Active, not recruiting |
Study Name: Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Condition: Adult Grade III Lymphomatoid Granulomatosis Adult Nasal Type Extranodal NK/T-cell Lymphoma Date: 2013-02-27 Interventions: Drug: brentuximab vedotin Give |
Recruiting |
Study Name: Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease Condition: Hairy Cell Leukemia Splenic Marginal Zone Lymphoma Date: 2012-10-31 |
Active, not recruiting |
Study Name: BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia Condition: Hairy Cell Leukemia Date: 2012-10-17 Interventions: Drug: Vemurafenib Patients will receive vemurafenib at a dose of 960mg orally b.i.d. continuously in cyc |